Key result
Tenecteplase administration for acute ischaemic stroke was followed by the development of an inferolateral ST elevation myocardial infarction in a male patient in his 50s.
Why the study?
MI secondary to thrombolysis for acute ischaemic stroke has been documented with alteplase, but there were no documented reports of MI secondary to tenecteplase.
Case Report (n=1)
This is the first documented report of a patient developing an ST-elevation myocardial infarction as a severe complication of Tenecteplase therapy for acute ischaemic stroke.
Myocardial infarction (MI) secondary to thrombolytic therapy in the setting of acute ischaemic stroke (AIS) is a rare but severe complication. This phenomenon has been well documented in the past with recombinant tissue-type plasminogen activator, also known as Alteplase. However, there are no documented reports of MI secondary to Tenecteplase (TNKase), an alternative thrombolytic agent rapidly gaining favour in managing AIS. We report a male patient in his 50s who received TNKase for an AIS and subsequently developed an inferolateral ST elevation MI.
No takes yet. Share an insight, caveat, or question.
FRÍAS et al. (2023) conducted a case report in Acute ischaemic stroke (n=1). Tenecteplase was evaluated on ST elevation myocardial infarction. Tenecteplase administration for acute ischaemic stroke was followed by the development of an inferolateral ST elevation myocardial infarction in a male patient in his 50s.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: